INTRAORAL DELIVERY – Utilization of Intraoral Administration for Enablement & Enhancement of Drug Delivery – Highlights of Recent Commercial Products
Zhen Yang, PhD, and Yunhui Wu, PhD, highlight several commercialized intraoral formulations from a clinical pharmacokinetic perspective and reveal its mechanism for enablement or enhancement of drug delivery via intraoral administration.
Scott D. Barnhart indicates the buccal and sublingual oral mucosa will continue to be an area of growing interest for drug delivery as researchers evaluate ways to improve bioavailability, patient compliance, and product lifecycle beyond tablet and injectable formats.
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
Marshall Crew, PhD, says that although diffusion processes of innovative products and services have been studied extensively for nearly 45 years, it seems reasonable that we might learn from others’ observations, and the frameworks they’ve developed to model diffusion of technology for the adoption of bioavailability platforms.
Sam de Costa, PhD, believes the launch of two stabilization and drug delivery platforms that have the potential to revolutionize the delivery of vaccines, therapeutics, and diagnostics, while significantly cutting costs, has attracted sharp interest from pharmaceutical and biotech companies around the world.
Tugrul T. Kararli, PhD, MBA; Kurt Sedo; and Josef Bossart, PhD; believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and in a series of three articles, examine the past, present, and future of these products with the intent of understanding their whats and whys.
EXECUTIVE INTERVIEW – Hermes Pharma: User-Friendly Dosage Forms, a Win-Win Situation for Patients & Pharma
Drug Development Executive: Dr. Thomas Hein, Director, Sales & Business Development at Hermes Pharma, discusses how user-friendly dosage forms help put patients first, their advantages for patients and pharmaceutical companies, as well as the challenges associated with their development and production.
Drug Development Executive: Andreas Schütte, Member of the Management Board, Plastics & Devices Division, discusses his important role in Gerresheimer’s divisional restructuring process, and how he is convinced the new structure better reflects customer requirements.
PREFILLABLE SYRINGE TECHNOLOGY – BD Neopak – Delivering the Next Generation in Glass Prefillable Syringes
Justin M. Wright, PhD, and Herve Soukiassian highlight significant development and commercial manufacturing investments in glass PFS container technology for the biotech industry with three key areas of focus: reducing overall variability, reducing SbVPs, and increasing glass strength and durability performance.
Chris Hurlstone says device developers – whether human factors experts or industrial designers, mechanical engineers, or risk analysis teams – know engineering of the click is critical, yet this aspect of device design, like many others, is frequently not given the attention it deserves.
EXCLUSIVE ONLINE CONTENT
Lonza recently announced a $93-million investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry…..
WEBINAR SERIES ALERT – Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts – Free Oct-Nov Webinar Series
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Proveris Scientific Research Collaboration: New Generation Technologies for Improved Measurement of Pharmaceutical Aerosols
Proveris Scientific Corporation recently announced its research collaboration with The University of Sydney and Macquarie University on a project to develop a new generation of technologies for improving….
Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….